Prognostic Value of APACHE IV Score in Patients Bridged to Heart Transplantation on ECMO

医学 阿帕奇II 接收机工作特性 切断 内科学 心脏移植 比例危险模型 体外膜肺氧合 对数秩检验 生存分析 移植 死亡率 重症监护室 量子力学 物理
作者
Andrea Lechiancole,Claudio Russo,Guido Maria Olivieri,Massimo Maccherini,Serafina Valente,Davide Pacini,Sofia Martìn Suàrez,Massimo Boffini,Matteo Marro,Stefano Pelenghi,Pasquale Totaro,Miriam Isola,Maria De Martino,Uberto Bortolotti,Ugolino Livi,Igor Vendramin
出处
期刊:Clinical transplantation [Wiley]
卷期号:38 (6)
标识
DOI:10.1111/ctr.15370
摘要

ABSTRACT Background Methods for risk stratification of candidates for heart transplantation (HTx) supported by extracorporeal membrane oxygenation (ECMO) are limited. We evaluated the reliability of the APACHE IV score to identify the risk of mortality in this patient subset in a multicenter study. Methods Between January 2010 and December 2022, 167 consecutive ECMO patients were bridged to HTx; they were divided into two groups, according to a cutoff value of APACHE IV score, obtained by receiver operating characteristic curve analysis for 90‐day mortality. Kaplan–Meier survival curves were plotted, and compared through the log‐Rank test. Cox regression model was used to estimate which factors were associated with survival. Results The 90‐day mortality prediction of the APACHE IV score showed an area under the curve of 0.87 (95% CI: 0.80–0.94), with a cutoff value of 49 (specificity 91.7%–sensibility 69.6%). 125 patients (74.8%) showed an APACHE IV score value < 49 (Group A), and 42 (25.2%) ≥ 49 (Group B). 90‐day mortality was 11.2% in Group A and 76.2% in Group B ( p < 0.01). Survival at 1 and 5 years was 85.5%, 77% versus 23.4%, 23.4% ( p < 0.01) in Groups A and B. Mortality correlated at univariable analysis with recipient age, body mass index, mechanical ventilation, APACHE IV score, and platelets number. At multivariable analysis only APACHE IV score (HR: 1.07 [1.05–1.09, 95% CI]) independently affected survival. Conclusions The APACHE IV score represents a powerful predictor of survival in patients bridged to HTx on ECMO support, and could guide candidacy of patients on ECMO.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ava应助李瑶采纳,获得10
刚刚
有空发布了新的文献求助10
刚刚
Memory发布了新的文献求助10
1秒前
1秒前
努力搬砖发布了新的文献求助30
1秒前
1秒前
等待晓筠完成签到,获得积分10
2秒前
Xenia发布了新的文献求助10
3秒前
缥缈的水彤完成签到,获得积分10
3秒前
ding应助czyhii采纳,获得10
3秒前
糕糕发布了新的文献求助10
4秒前
4秒前
4秒前
张三发布了新的文献求助80
6秒前
6秒前
7秒前
7秒前
8秒前
搞怪城完成签到,获得积分10
8秒前
9秒前
jjjie发布了新的文献求助10
9秒前
lili完成签到,获得积分10
9秒前
思源应助huahua采纳,获得10
9秒前
9秒前
yanpengbaba发布了新的文献求助10
11秒前
11秒前
11秒前
Jasper应助Xenia采纳,获得10
12秒前
lili发布了新的文献求助10
12秒前
12秒前
chry1sa完成签到,获得积分10
13秒前
纯真电源发布了新的文献求助10
15秒前
脑洞疼应助摸俞采纳,获得10
16秒前
朱良宇发布了新的文献求助10
17秒前
科研圣体完成签到,获得积分20
17秒前
CipherSage应助傻子与白痴采纳,获得10
18秒前
孙笑川258完成签到 ,获得积分20
19秒前
科研通AI6.3应助yanpengbaba采纳,获得10
19秒前
123发布了新的文献求助10
20秒前
烟花应助千里采纳,获得10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
Electrode Potentials 550
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6963121
求助须知:如何正确求助?哪些是违规求助? 8645234
关于积分的说明 18335410
捐赠科研通 6413186
什么是DOI,文献DOI怎么找? 3086646
关于科研通互助平台的介绍 2135812
邀请新用户注册赠送积分活动 2063091